Basic Fibroblast Growth Factor
Also known as: Basic FGF, bFGF, FGF-2, FGF2, FGFB, Fiblast, Heparin-binding growth factor 2 (HBGF-2), Trafermin
Source Basic Fibroblast Growth Factor at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Basic fibroblast growth factor (bFGF, FGF‑2) is a naturally occurring protein that stimulates cell proliferation, angiogenesis and tissue repair. It is approved as a prescription drug and is being investigated in regenerative medicine approaches for skin disorders such as androgenetic alopecia and vitiligo, for dental pulp regeneration, and as an adjunct to platelet‑rich plasma in wound‑healing protocols.
Mechanism of Action
bFGF binds to fibroblast growth factor receptors (FGFR1‑4) on the surface of fibroblasts, endothelial cells and progenitor cells. Receptor activation triggers downstream MAPK/ERK and PI3K‑Akt pathways, driving cellular proliferation, migration and new‑blood‑vessel formation. Isoforms generated by alternative translation have distinct intracellular localisations, but all promote angiogenic and mitogenic signals that support tissue regeneration and repair.
What the Research Shows
A 2024 systematic review of dermatologic randomized trials identified combination PRP + bFGF among several regenerative strategies that reported up to 68% improvement in androgenetic alopecia and 71% in vitiligo, although the contribution of bFGF alone was not isolated. A 2024 network meta‑analysis of regenerative endodontic therapy found that blood‑clot scaffolds supplemented with bFGF achieved the highest success for long‑term outcomes such as root lengthening beyond 12 months, albeit with very low‑to‑low confidence due to limited trial numbers. A 2023 review of FGF2 isoforms described its fundamental role in growth and differentiation across tissues. Earlier work highlighted bFGF as a prototypic angiogenic factor. Recent vitiligo literature lists bFGF as an emerging, but not yet established, therapy, while a 2025 Canadian consensus placed bFGF among interventions that are not recommended for androgenetic alopecia.
Reported Benefits
Clinical data suggest bFGF can enhance angiogenesis and cellular proliferation, potentially improving hair regrowth when combined with PRP, accelerating repigmentation in vitiligo, and supporting dentin‑pulp complex regeneration when incorporated into scaffolds. In endodontic studies, bFGF‑augmented scaffolds were associated with better root development and radiographic healing over longer follow‑up periods.
Limitations of the Evidence
Evidence for bFGF is largely derived from combination protocols; isolated bFGF trials are scarce. Reported benefits come from small, heterogeneous studies with low to very low confidence levels. Long‑term safety and efficacy data are lacking, and consensus statements have not endorsed bFGF as a standard therapy for hair loss or skin disorders. Further high‑quality randomized trials are needed.
Safety Considerations
The reviewed dermatologic and dental studies reported few serious adverse events, but detailed safety profiles for bFGF alone were not provided. As a growth factor, theoretical risks include excessive angiogenesis or unwanted tissue proliferation. Caution is advised in patients with active malignancy or uncontrolled vascular disease until more robust safety data become available.
How It Is Administered
bFGF is formulated for several routes, including intracoronary, intramuscular, intravenous, subcutaneous injection and topical application. In dermatologic and dental research it is typically delivered as an injectable solution mixed with platelet‑rich plasma or incorporated into a scaffold matrix. Topical preparations have been explored for skin lesions, while systemic routes are used experimentally for vascular indications.
Routes of Administration
Goals & Uses
- Wound Healing / Pressure Ulcer TreatmentDermatology / Tissue RepairHigh
- Angiogenesis promotionVascularModerate
- Angiogenesis / NeovascularizationCardiovascularModerate
- Neuroprotection and Neural RepairNeurologyLow
- Wound healing accelerationRegenerative MedicineModerate
- Bone and Cartilage RegenerationOrthopedicsModerate
- Burns TreatmentDermatology / Wound CareHigh
- Stem Cell Maintenance and ExpansionCell Biology / ResearchHigh
Contraindications
- Active malignancyOncologyHighUse caution or avoid depending on agent and context
- Hypersensitivity to bFGF or Formulation ExcipientsAllergy / ImmunologyHigh
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
- Proliferative RetinopathyOphthalmologyModerate
Adverse Effects
- Fever / PyrexiaSystemicUncommon
- EdemaFluid BalanceUnknownSwelling from fluid retention
- ProteinuriaRenalUncommon
- Local Injection Site ReactionsDermatologicalCommon
- Antibody FormationImmunologicalUncommon
- HypotensionCardiovascularUncommonLow blood pressure
- Theoretical Oncogenic RiskOncologyUnknown
Drug Interactions
- HeparinModerate
- CorticosteroidsModerate
- VEGF Inhibitors (e.g., Bevacizumab)Low
Population Constraints
- Pediatric patientsAgeRelative
- Pregnant and Lactating WomenReproductiveRelative
- Diabetic PatientsMetabolicRelative
- Patients with History of MalignancyOncologyRelative
Regulatory Status
- European UnionInvestigationalClinical studies ongoing for chronic wounds.
- United StatesInvestigationalPhase I/II trials for peripheral artery disease.
- United KingdomInvestigationalResearch use only.
Not approved for therapeutic use; investigated in clinical trials for ischemic disease and wound repair.
Evidence & Sources
- Journal ArticleHighJafarzadeh A, et al.2024-01-01T00:00:00.000000Z
- Journal ArticleModerateNickle A, Ko S, Merrill AE2024-01-01T00:00:00.000000Z
- Journal ArticleModerateFolkman J, Klagsbrun M1987-01-01T00:00:00.000000Z
- Journal ArticleHighSabeti M, et al.2024-01-01T00:00:00.000000Z
- Journal ArticleModeratePerez-Bootello J, et al.2023-01-01T00:00:00.000000Z
- Journal ArticleLowLandells I, et al.2025-01-01T00:00:00.000000Z
Frequently Asked Questions
Is basic fibroblast growth factor an approved drug for hair loss?
No. Although bFGF is an approved prescription product, regulatory agencies have not approved it specifically for androgenetic alopecia. Current recommendations list it among non‑recommended interventions pending stronger evidence.
How does bFGF differ from other growth factors used in wound healing?
bFGF primarily activates FGFR‑mediated pathways that drive fibroblast proliferation and angiogenesis. Unlike acidic FGF, it has a high affinity for heparan‑sulfate proteoglycans, which helps retain it in extracellular matrices and may prolong its local activity.
Can bFGF be used safely in patients with cancer?
The available studies do not provide specific safety data for cancer patients, and because bFGF promotes blood‑vessel growth, caution is advised. Use in individuals with active malignancy is not recommended until dedicated safety studies are completed.
What form of bFGF is used in dental regenerative procedures?
In regenerative endodontic therapy, bFGF is typically added to a blood‑clot scaffold or other biomaterial and applied directly into the root canal space to stimulate pulp‑like tissue formation and continued root development.
What is Basic Fibroblast Growth Factor?
Basic fibroblast growth factor (bFGF, FGF‑2) is a naturally occurring protein that stimulates cell proliferation, angiogenesis and tissue repair. It is approved as a prescription drug and is being investigated in regenerative medicine approaches for skin disorders such as androgenetic alopecia and vitiligo, for dental pulp regeneration, and as an adjunct to platelet‑rich plasma in wound‑healing protocols.
What is Basic Fibroblast Growth Factor used for?
Basic Fibroblast Growth Factor is educationally associated with: Wound Healing / Pressure Ulcer Treatment, Angiogenesis promotion, Angiogenesis / Neovascularization, Neuroprotection and Neural Repair, Wound healing acceleration, Bone and Cartilage Regeneration, Burns Treatment, Stem Cell Maintenance and Expansion. Educational only — not medical advice.
How is Basic Fibroblast Growth Factor administered?
Recorded routes of administration: Intracoronary, Intramuscular, Intravenous, Subcutaneous, Topical.
What are the potential side effects of Basic Fibroblast Growth Factor?
Reported adverse effects include: Fever / Pyrexia, Edema, Proteinuria, Local Injection Site Reactions, Antibody Formation, Hypotension, Theoretical Oncogenic Risk. This list is not exhaustive — consult a qualified clinician.
Who should avoid Basic Fibroblast Growth Factor?
Recorded contraindications: Active malignancy, Hypersensitivity to bFGF or Formulation Excipients, Pregnancy, Proliferative Retinopathy. Consult a qualified clinician before use.